Our ML/AI enabled platform transforms life-changing therapies into accessible oral formulations.
Our oral biologic platform creates substantial value across the entire healthcare ecosystemโfrom patients to payers to providers.
The patient experiences the most direct "quality of life" improvements.
Approximately 10% of the population suffers from needle phobia, which can lead to treatment avoidance. Oral delivery removes this critical barrier to therapy.
Patients can take their medication at home, at work, or while traveling, rather than scheduling appointments at infusion centers or clinics.
Oral delivery avoids the bruising, swelling, and localized pain common with subcutaneous injections and IV lines.
Bypasses the risk of cannula-related infections or secondary bacterial/fungal infections associated with repeated skin punctures.
Research suggests patients are more likely to stick to a long-term treatment plan when it involves a simple pill rather than a complex or painful injection schedule.
For certain drugs like insulin, oral delivery can better mimic the body's natural pathways (portal circulation to the liver) rather than systemic absorption via fat tissue.
Payers see significant value in reducing the "hidden" costs of healthcare.
Oral formulations often do not require the same sterile manufacturing environments as parenterals, potentially lowering the base price of the drug.
Payers no longer have to reimburse for nursing time, facility fees for infusion centers, or specialized equipment (needles, syringes, IV kits).
Lowering the rate of injection-site infections or infusion-related adverse reactions reduces the cost of secondary care.
The introduction of oral versions of existing biologics can drive competition and lower prices across the therapeutic class.
The broader system benefits from improved efficiency and resource allocation.
Frees up nurses and clinicians from the time-consuming task of administering injections and monitoring patients during long infusions.
Reduces the need for dedicated infusion chairs and clinic space, allowing hospitals to focus resources on patients with more acute needs.
Eliminates the medical waste associated with disposables like needles, biohazard sharps containers, and plastic IV tubing.
Because oral meds are easier to prescribe and take, doctors may be able to start effective biologic therapy earlier in the disease progression, potentially preventing long-term disability or expensive hospitalizations.
Leveraging machine learning and artificial intelligence to revolutionize how biologics are formulated and delivered.
Traditional formulation development relies on trial-and-error approaches that take years and millions of dollars. Our ML platform analyzes thousands of molecular interactions simultaneously, predicting optimal formulation parameters in weeks, not years.
By integrating physicochemical properties, biological pathways, and delivery kinetics, our AI identifies the precise combination of excipients, protective coatings, and release mechanisms needed for each unique biologic.
AI algorithms predict formulation success rates before synthesis
Machine learning accelerates formulation cycles from years to months
Continuous learning from experimental results improves platform accuracy
AI analyzes molecular structure, stability, and absorption properties
ML models generate optimal excipient combinations and coating strategies
Virtual simulations predict gastric protection and intestinal release
Experimental data feeds back into models for continuous improvement
Our diverse pipeline targets multiple high-impact therapeutic areas with significant unmet medical needs.
Oral anti-TNF monoclonal antibody formulation
Oral integrin antagonist for Crohn's and UC
Oral PCSK9 inhibitor for cardiovascular disease prevention
Oral checkpoint inhibitor immunotherapy platform
We're actively seeking strategic partnerships with pharmaceutical companies, research institutions, and investors who share our vision of transforming biologic drug delivery.
Interested in partnering with Oralyx Bio? We'd love to explore collaboration opportunities in drug development, licensing, or investment.
Contact UsWorld-class expertise in drug formulation, ML/AI, and drug-device combination products.
Former VP of Formulation Sciences at a leading biotech company with 15+ years developing novel drug delivery systems. Led development of 12 approved products and holds multiple patents in oral biologic delivery. PhD in Pharmaceutical Sciences from MIT.
Leading venture firms invest in revolutionary oral biologic delivery platform, accelerating pipeline development and bringing the company's ML-enabled formulation technology closer to clinical trials.
Interested in partnerships, investment opportunities, or learning more? We'd love to hear from you.
Malvern, PA 19355
United States
info@oralyxbio.com
partnerships@oralyxbio.com